Clinical Evaluation of Belzupacap Sarotalocan (AU-011), a First-in-Class Targeted Therapy for Choroidal Melanoma with Intravitreal or Suprachoroidal Route of Administration
Archives: Company News
Company news stories
ISOO 2022: Educational Session Highlighting Retrospective Study of Belzupacap Sarotalocan versus Radiotherapy in Choroidal Melanoma
Topline Data from a Retrospective, Matched Case Study Evaluating Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy, Supports the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma
ISOO 2022: Dr. Kim Presents Phase 2 SC AU-011 Data
A Phase 2 Trial of belzupacap sarotalocan (AU-011), a First-in-class Targeted Therapy for Choroidal Melanoma via Suprachoroidal (SC) Administration
ISOO 2022: Dr. Shields Presents Phase 1b/2 IVT AU-011 Data
A Phase 1b/2 Trial of belzupacap sarotalocan (AU-011), a First-in-Class Targeted Therapy for the Treatment of Choroidal Melanoma via Intravitreal Administration
ARVO 2022: Aura Preclinical Data Presented
A First in Class Virus-Like Drug Conjugate (VDC) Shows Anti-tumor Activity in Cancers that Commonly Metastasize to the Choroid
AACR 2022: Aura Preclinical Data Presented
Biological assessment of the virus-like drug conjugate AU-011 to specifically target a breadth of human cancer types
ASCO GU 2022: Aura Preclinical Data Presented
Targeting urothelial neoplasia using an investigational virus-like drug conjugate
AAO 2021: Dr. Shields Presents Phase 1b/2 IVT AU-011 Data
A Phase 1b/2 Trial of AU-011, an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using Intravitreal Administration
AAO 2021: Dr. Demirci Presents Phase 2 SC AU-011 Data
A Phase 2 Trial of AU-011, an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using Suprachoroidal Administration
Aura Biosciences Announces Pricing of Initial Public Offering
Cambridge, MA – October 28, 2021 – Aura Biosciences, Inc. (“Aura”), a clinical-stage oncology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the pricing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aura, are expected to be $75.6 million. All of the shares are being offered by Aura. In addition, Aura has granted the underwriters a 30-day option to purchase up to an additional 810,000 shares of common stock at the initial public offering price less underwriting discounts and commissions.
The shares are expected to begin trading on the Nasdaq Global Market on October 29, 2021 under the ticker symbol “AURA.” The offering is expected to close on November 2, 2021, subject to the satisfaction of customary closing conditions.
Cowen, SVB Leerink and Evercore ISI are acting as joint book-running managers for the offering, and BTIG is acting as lead manager for the offering.
The registration statements relating to these securities became effective on October 28, 2021. The offering will be made only by means of a prospectus, copies of which may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com; SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbleerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055; by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The VDC technology platform is based on the discoveries of NIH Distinguished Investigator Dr. John Schiller of the Center for Cancer Research at the National Cancer Institute. The company has the goal of developing this technology in multiple cancer indications with an initial focus on primary choroidal melanoma, a rare disease for which there are no approved drugs. Aura’s lead product candidate belzupacap sarotalocan (AU-011) is currently in Phase 2 development for the first line treatment of primary choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. AU-011 was well tolerated in a Phase 1b/2 trial, demonstrating high rates of tumor control and vision preservation. Future pipeline applications for Aura’s technology include additional ocular oncology indications like choroidal metastases and solid tumor indications like non-muscle invasive bladder cancer. Aura is headquartered in Cambridge, MA.
Investor and Media Contact:
Matthew DeYoung
Argot Partners
212-600-1902 | aura@argotpartners.com